These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22266779)

  • 21. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).
    Polli JW; Olson KL; Chism JP; John-Williams LS; Yeager RL; Woodard SM; Otto V; Castellino S; Demby VE
    Drug Metab Dispos; 2009 Feb; 37(2):439-42. PubMed ID: 19056914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the P-glycoprotein- and breast cancer resistance protein-mediated brain penetration of 11C-labeled topotecan using small-animal positron emission tomography.
    Yamasaki T; Fujinaga M; Kawamura K; Hatori A; Yui J; Nengaki N; Ogawa M; Yoshida Y; Wakizaka H; Yanamoto K; Fukumura T; Zhang MR
    Nucl Med Biol; 2011 Jul; 38(5):707-14. PubMed ID: 21718946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters.
    Polli JW; Baughman TM; Humphreys JE; Jordan KH; Mote AL; Webster LO; Barnaby RJ; Vitulli G; Bertolotti L; Read KD; Serabjit-Singh CJ
    Drug Metab Dispos; 2004 Jul; 32(7):722-6. PubMed ID: 15205387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.
    Vautier S; Lacomblez L; Chacun H; Picard V; Gimenez F; Farinotti R; Fernandez C
    Eur J Pharm Sci; 2006 Feb; 27(2-3):167-74. PubMed ID: 16263252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and in vivo evaluation of ¹⁸F-fluoroethyl GF120918 and XR9576 as positron emission tomography probes for assessing the function of drug efflux transporters.
    Kawamura K; Yamasaki T; Konno F; Yui J; Hatori A; Yanamoto K; Wakizaka H; Ogawa M; Yoshida Y; Nengaki N; Fukumura T; Zhang MR
    Bioorg Med Chem; 2011 Jan; 19(2):861-70. PubMed ID: 21185730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
    Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
    J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats.
    Reichel V; Burghard S; John I; Huber O
    Brain Res; 2011 Jan; 1370():238-45. PubMed ID: 21075088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine.
    Pan G; Giri N; Elmquist WF
    Drug Metab Dispos; 2007 Jul; 35(7):1165-73. PubMed ID: 17437964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
    Yamasaki T; Kawamura K; Hatori A; Yui J; Yanamoto K; Yoshida Y; Ogawa M; Nengaki N; Wakisaka H; Fukumura T; Zhang MR
    Nucl Med Commun; 2010 Nov; 31(11):985-93. PubMed ID: 20859232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of antiepileptic drugs in knockout mouse models.
    Nakanishi H; Yonezawa A; Matsubara K; Yano I
    Eur J Pharmacol; 2013 Jun; 710(1-3):20-8. PubMed ID: 23588114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
    Yousif S; Chaves C; Potin S; Margaill I; Scherrmann JM; Declèves X
    J Neurochem; 2012 Nov; 123(4):491-503. PubMed ID: 22845665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
    Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
    Gong IY; Mansell SE; Kim RB
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):164-70. PubMed ID: 22958812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
    Xia CQ; Liu N; Yang D; Miwa G; Gan LS
    Drug Metab Dispos; 2005 May; 33(5):637-43. PubMed ID: 15716365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.